Immunome, Inc. (IMNM)
| Market Cap | 2.26B |
| Revenue (ttm) | 4.01M |
| Net Income (ttm) | -224.59M |
| Shares Out | 113.25M |
| EPS (ttm) | -2.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,334,646 |
| Open | 19.45 |
| Previous Close | 19.40 |
| Day's Range | 19.35 - 20.44 |
| 52-Week Range | 7.96 - 27.65 |
| Beta | 2.07 |
| Analysts | Strong Buy |
| Price Target | 35.77 (+79.21%) |
| Earnings Date | Aug 5, 2026 |
About IMNM
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including I... [Read more]
Financial Performance
In 2025, Immunome's revenue was $6.94 million, a decrease of -23.23% compared to the previous year's $9.04 million. Losses were -$212.39 million, -27.50% less than in 2024.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for IMNM stock is "Strong Buy." The 12-month stock price target is $35.77, which is an increase of 79.21% from the latest price.
News
Immunome announces first patient dosed in Phase 1 trial of IM-1617
Immunome (IMNM) announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1617, a potential first-in-class ADC directed at an undisclosed solid tumor target and…
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the fir...
Immunome Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals approved by shareholders. No questions were submitted, and voting results will be reported in a Form 8-K filing.
Immunome Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Varegacestat is nearing commercial launch with strong phase III data in desmoid tumors, including rapid pain reduction and a favorable safety profile. The ADC pipeline is advancing, with IM-1021 data expected this year and multiple solid tumor programs progressing. Cash runway extends into 2028, supporting broad development plans.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced toda...
Immunome announces Ringside trial met primary, secondary endpoints
Immunome (IMNM) announced detailed efficacy and safety results from Ringside, the global, randomized, double-blind, placebo-controlled Phase 3 trial of varegacestat in patients with progressing desmoi...
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced detailed eff...
Immunome Slides: Investor presentation
Immunome has posted slides in relation to its latest quarterly earnings report, which was published on May 29, 2026.
Immunome price target raised to $37 from $36 at Truist
Truist raised the firm’s price target on Immunome (IMNM) to $37 from $36 and keeps a Buy rating on the shares. The firm is positive on the potential of varegacestat’s…
Immunome initiated with an Overweight at Barclays
Barclays analyst Lukas Shumway initiated coverage of Immunome (IMNM) with an Overweight rating and $36 price target Immunome is a biopharmaceutical company focused primarily on the development of anti...
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members o...
Immunome price target lowered to $33 from $37 at Leerink
Leerink analyst Andrew Berens lowered the firm’s price target on Immunome (IMNM) to $33 from $37 and keeps an Outperform rating on the shares.
Immunome reports Q1 EPS (48c), consensus (54c)
“This quarter reflects the progress we are making in building Immunome (IMNM) into a multi-program targeted oncology company,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Imm...
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu...
Immunome Earnings release: Q1 2026
Immunome released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Immunome Quarterly report: Q1 2026
Immunome has published its Q1 2026 quarterly earnings report on May 12, 2026.
Immunome announces submission of NDA for varegacestat in desmoid tumors
Immunome (IMNM) announced the submission of a New Drug Application to the U.S. Food and Drug Administration for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor, for the tr...
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the submissi...
Immunome Proxy statement: Proxy filing
Immunome filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Immunome Proxy statement: Proxy filing
Immunome filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced...
Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead
Immunome stock shows renewed strength after a pennant breakout, signaling a potential continuation of its recovery trend with upside momentum building toward prior highs.
Immunome Transcript: Leerink Global Healthcare Conference 2026
Varegacestat, a once-daily gamma secretase inhibitor, showed strong phase III results in desmoid cancer and is on track for FDA submission and potential launch by year-end. The pipeline includes next-gen ADCs, with ROR1 ADC data expected this year, and global commercialization strategies are in place.
Immunome price target lowered to $30 from $32 at Lake Street
Lake Street analyst Chad Messer lowered the firm’s price target on Immunome (IMNM) to $30 from $32 and keeps a Buy rating on the shares. Strategic execution remains on track,…
Immunome price target raised to $36 from $33 at Craig-Hallum
Craig-Hallum analyst Adam Vogel raised the firm’s price target on Immunome (IMNM) to $36 from $33 and keeps a Buy rating on the shares. The firm notes Immunome reported FY25…